Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ZIOPHARM Oncology Inc.    ZIOP

ZIOPHARM ONCOLOGY INC. (ZIOP)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

ZIOPHARM to Present at the Stifel 2017 Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 10:06pm CET

BOSTON, Nov. 10, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that David Mauney, M.D., CBO and interim COO, will present at the Stifel 2017 Healthcare Conference in New York on Tuesday, November 14, 2017 at 11:00 a.m. ET.

To access a live audio webcast of the presentation, please visit the Investor Relations section at www.ziopharm.com. The webcast will be archived for 90 days.

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing innovative gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® (RTS®) technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.

Contact:
David Pitts
Argot Partners
212-600-1902
[email protected]


© GlobeNewswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ZIOPHARM ONCOLOGY INC.
02/15ZIOPHARM ONCOLOGY : to Announce Fourth Quarter and Full Year 2017 Year-end Finan..
AQ
02/14ZIOPHARM ONCOLOGY INC. : Wired News – Ziopharm Oncology Presents Data on Rapid P..
AC
02/14ZIOPHARM ONCOLOGY : Presents Data on Very Rapid Production of CAR T Cells at Key..
AQ
02/13Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Fina..
GL
02/12ZIOPHARM ONCOLOGY PRESENTS DATA ON V : T Cells and Beyond
AQ
02/07ZIOPHARM ONCOLOGY : Addresses Rumors and Stock Volatility Affirms 2018 Guidance
AQ
02/07ZIOPHARM ONCOLOGY : Addresses Rumors and Stock Volatility, Affirms 2018 Guidance
AQ
02/06ZIOPHARM ONCOLOGY, INC. (NASDAQ : ZIOP) Files An 8-K Financial Statements and Ex..
AQ
02/06ZIOPHARM ONCOLOGY INC : Other Events, Financial Statements and Exhibits (form 8-..
AQ
02/06Ziopharm Oncology Addresses Rumors and Stock Volatility, Affirms 2018 Guidanc..
GL
More news
News from SeekingAlpha
02/12Ziopharm's Sleeping Beauty system generates CAR-T cells in less than two days.. 
02/06Ziopharm says no plans for equity offering; shares up 4% 
02/02Gene therapy players under early pressure 
01/30Solid Biosciences slips on potential AAV toxicity 
01/24CAR-T Developers  Continue To Fly 
Financials ($)
Sales 2017 6,46 M
EBIT 2017 -58,2 M
Net income 2017 -73,0 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 84,2x
Capi. / Sales 2018 99,8x
Capitalization 544 M
Chart ZIOPHARM ONCOLOGY INC.
Duration : Period :
ZIOPHARM Oncology Inc. Technical Analysis Chart | ZIOP | US98973P1012 | 4-Traders
Technical analysis trends ZIOPHARM ONCOLOGY INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 7,25 $
Spread / Average Target 89%
EPS Revisions
Managers
NameTitle
Laurence James Neil Cooper Chief Executive Officer
David M. Mauney Executive VP, Chief Operating & Business Officer
Kevin G. Lafond Principal Financial Officer & Treasurer
Francois Lebel Chief Medical Officer, EVP-Research & Development
Murray F. Brennan Lead Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ZIOPHARM ONCOLOGY INC.-6.28%544
GILEAD SCIENCES14.21%105 388
VERTEX PHARMACEUTICALS4.94%40 647
REGENERON PHARMACEUTICALS-12.04%35 686
BIOVERATIV INC91.99%11 211
GENMAB4.28%10 654